Adalimumab alleviates skin pain in patients with moderate‐to‐severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2018.05.015
Abstract: To the Editor: Skin pain among patients with hidradenitis suppurativa (HS) is prevalent, severe, and a recommended target for treatment. Adalimumab has been approved for moderate-to-severe HS in the United States and Europe on the… read more here.
Keywords: adalimumab alleviates; hidradenitis suppurativa; pain; moderate severe ... See more keywords